

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

19-386/S015

Trade Name: Brevibloc Injection 2500mg/ML and 100mg/10mL

Generic Name: Esmolol Hydrochloride

Sponsor: Baxter Pharmaceutical Products inc.

Approval Date: February 23, 2000

Indications: Short-Term control of heart rate in patients with abnormally fast heart rhythms such as atrial fibrillation, atrial flutter or sinus tachycardia.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
19-386/Supplement 15

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Approvable Letter	
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

19-386/S015

APPROVAL LETTER

FEB 23 2000

NDA 19-386/S-015

Baxter Pharmaceutical Products Inc.
Attention: Ms. Priya Jambhekar
95 Spring Street
New Providence, NJ 07974

Dear Ms. Jambhekar:

Please refer to your August 26, 1999 supplemental new drug application submitted under section 505 (b) of the Federal Food, Drug, and Cosmetic Act for Brevibloc (esmolol HCL) Injection, 2500 mg/10 mL and 100 mg/10 mL.

The supplemental application provides for new alternative testing laboratories (Baxter Pharmaceutical Products, Inc., Memphis, TN and Baxter Healthcare Corporation, Cleveland, MS) for release and stability testing of the drug product.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Sincerely yours,

K. Srinivasachar 2-23-00

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I
Division of Cardio-Renal Drug Products (HFD-110)
Office of New Drug Chemistry
Center for Drug Evaluation and Research

NDA 19-386/S-015 - Page 2

CC:

Original NDA 19-386/S-015

HFD-110/Division File

HFD-110/Project Manager

HFD-110/JAdvani

HFD-95

DISTRICT OFFICE

HFD-810/Jsimmons

Init. by: Ksrinivasachar

Drafted by: SO/2/23/00

Approval Date: 12/31/86

APPROVAL

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

19-386/S015

CHEMISTRY REVIEW(S)

JAN 3 - 2000

CHEMIST'S REVIEW		1. ORGANIZATION HFD-110	2. NDA Number 19-386
3. Name and Address of Applicant (City & State) Baxter Pharmaceutical Products Inc. 95 Spring Street New Providence, NJ 07974		4. Supplement(s) Number(s) Date(s) SCM-015 8/26/99	
5. Drug Name Brevibloc	6. Nonproprietary Name Esmolol HCl	7. Amendments & Other (reports, etc) - Dates	
8. Supplement Provides For: in a following laboratories for conducting release and/or stability testing of finished product.			
9. Pharmacological Category Anti-adrenergic (β receptor)	10. How Dispensed <input checked="" type="checkbox"/> Rx <input type="checkbox"/> OTC	11. Related IND(s)/ NDA(s)/DMF(s)	
12. Dosage Form(s) Intravenous injection	13. Potency(ies) 250mg/mL 10mL amp 10 mg/mL 10mL vial		
14. Chemical Name and Structure methyl p-[2-hydroxy-(isopropylamino)propoxy] hydrocinnamate hydrochloride		15. Records/Reports Current <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Reviewed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
16. Comments Prior Approval Supplement The analytical testing will be conducted at: Baxter Pharmaceuticals Products Inc. 1710 N. Shelby Oaks Drive, Suite 1-6 Memphis, TN 38134-7402 The microbial testing will be conducted at: Baxter Healthcare Corporation IV Systems and Medical Products 911 North Davis Cleveland, MS 38732 GMPs certificates are included.			
17. Conclusions and Recommendations EER requested on 9/3/99. Inspection will not be done before 12/30/99 (see attached memo) and because this is the only CMC issue for this supplement the 4 month goal date will not be met.			
18. REVIEWER			
Name Danute G. Cunningham	Signature <i>Danute G. Cunningham</i>	Date Completed December 14, 1999	
Distribution: <input type="checkbox"/> Original Jacket <input type="checkbox"/> Reviewer <input type="checkbox"/> Division File <input type="checkbox"/> CSO			

19386S15.SUP

K. Swinicki
1-3-00

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

19-386/S015

**ADMINISTRATIVE and CORRESPONDENCE
DOCUMENTS**

FEB 23 2000

MEMORANDUM

Date: 23 Feb. 2000

From: K. Srinivasachar, Ph.D., Chemistry Team Leader, HFD-110

K. Srinivasachar 2-23-00

To: NDA 19-386, Brevibloc (esmolol HCl) Injection

Subject: Addendum to Chemistry Review dated 14 Dec 1999 by D. Cunningham for SCM-015

The EER for the 2 facilities listed was completed on 8 Feb 2000 with an overall Acceptable recommendation. Since this was the only pending issue the Supplement may now be approved.

Conclusions and Recommendations: Issue Approval letter for SCM-015.

CC:

Orig. NDA 19-386

HFD-110/ Div. File NDA 19-386

HFD-110/ K. Srinivasachar/Project Manager/J.Advani

FDA CDER EES
ESTABLISHMENT EVALUATION REQUEST
SUMMARY REPORT

Application: NDA 19386/015	Priority: 1P	Org Code: 110
Stamp: 30-AUG-1999 Regulatory Due: 30-DEC-1999	Action Goal:	District Goal: 25-NOV-1999
Applicant: BAXTER PHARM PROD	Brand Name: BREVIBLOC (ESMOLOL HCL) INJ	
110 ALLEN RD	Established Name:	
LIBERTY CORNER, NJ 079380804	Generic Name: ESMOLOL HYDROCHLORIDE	
	Dosage Form: INJ (INJECTION)	
	Strength: 250 MG/ML AND 10 MG/ML	
FDA Contacts: ID = 100846		, Review Chemist
K. SRINIVASACHAR (HFD-110)	301-594-5376	, Team Leader

Overall Recommendation:

ACCEPTABLE on 08-FEB-2000 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: 1041673	DMF No:	
BAXTER (PPI) DISTRIBUTION CENTI	AADA No:	
1710 N. SHELBY OAKS DRIVE, SUITE		
MEMPHIS, TN 38134-740		
Profile: CTL	OAI Status: NONE	Responsibilities: FINISHED DOSAGE RELEASE
Last Milestone: OC RECOMMENDATION		TESTER
Milestone Date: 21-JAN-2000		FINISHED DOSAGE STABILITY
Decision: ACCEPTABLE		TESTER
Reason: DISTRICT RECOMMENDATION		

Establishment: 1019003	DMF No:	
BAXTER HEALTHCARE CORP	AADA No:	
911 N DAVIS		
CLEVELAND, MS 38732		
Profile: CTL	OAI Status: NONE	Responsibilities: FINISHED DOSAGE STERILITY
Last Milestone: OC RECOMMENDATION		TESTER
Milestone Date: 08-FEB-2000		
Decision: ACCEPTABLE		
Reason: DISTRICT RECOMMENDATION		